Microbot Medical Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $15,140 thousand for the nine months ended that date, along with its first recorded revenues and an accumulated deficit of $119,226 thousand.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $15,140 thousand for the nine months ended September 30, 2026, compared to $9,678 thousand for the same period in 2025.
  • First revenues recorded: Revenues of $418 thousand were reported for the nine months ended September 30, 2026, versus $0 for the comparable 2025 period, though cost of revenues of $2,083 thousand produced a gross loss of $1,665 thousand.
  • Q3 2026 net loss: The net loss for the three months ended September 30, 2026, was $5,842 thousand, or $(0.09) per basic and diluted share.
  • Cash and marketable securities: As of September 30, 2026, cash and cash equivalents stood at $2,292 thousand and marketable securities at $59,536 thousand, down from $3,912 thousand and $74,680 thousand, respectively, at December 31, 2025.
  • Total shareholders' equity: Shareholders' equity decreased to $63,447 thousand as of September 30, 2026, from $77,554 thousand at December 31, 2025.
  • Shares outstanding: 67,164,801 shares of common stock at $0.01 par value were outstanding as of November 12, 2026.
  • Accumulated deficit: The accumulated deficit reached $119,226 thousand as of September 30, 2026, up from $104,086 thousand at December 31, 2025.

Microbot Medical's Financial Results for the Quarter and Nine Months Ended September 30, 2026

According to the filing, Microbot Medical Inc. (NASDAQ:MBOT) reported revenues for the first time in its comparative periods, recording $418 thousand for the nine months ended September 30, 2026. However, cost of revenues of $2,083 thousand resulted in a gross loss of $1,665 thousand. For the third quarter alone, revenues were $72 thousand against cost of revenues of $1,095 thousand, producing a gross loss of $1,023 thousand. The company attributed no revenues to either comparable 2025 period.

The filing disclosed operating expenses for the nine months ended September 30, 2026, including research and development of $4,781 thousand, sales and marketing of $5,257 thousand, and general and administrative expenses of $5,298 thousand, contributing to an operating loss of $17,001 thousand. This compares to an operating loss of $10,605 thousand for the nine months ended September 30, 2025. Financing income, net, partially offset losses, totaling $1,861 thousand for the nine-month 2026 period versus $611 thousand in the prior-year period.

On the balance sheet, total assets were $68,211 thousand as of September 30, 2026, compared to $81,544 thousand at December 31, 2025. Inventory grew to $3,213 thousand from $584 thousand, and accounts receivable of $90 thousand appeared where none was recorded at year-end 2025. The company reported total liabilities of $4,764 thousand as of September 30, 2026, up from $3,990 thousand at December 31, 2025. During the nine months ended September 30, 2026, the primary equity activity was share-based compensation of $1,017 thousand and a small at-the-market offering of 6,757 shares generating net proceeds of $16 thousand, according to the filing.

What Was Disclosed

Microbot Medical filed its Form 10-Q for the quarter ended September 30, 2026, reporting a nine-month net loss of $15,140 thousand, an accumulated deficit of $119,226 thousand, and first-recorded revenues of $418 thousand offset by a gross loss, with 67,164,801 shares outstanding as of November 12, 2026.